checkAd

     109  0 Kommentare NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA

    TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continued revenue growth to $3,573,751 for the quarter …

    TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continued revenue growth to $3,573,751 for the quarter and $13,846,329 year to date. Annual EBITDA was $1,067,247.

    Despite economic challenges in 2023, with most leading economies experiencing significant increases in inflation and suffering the negative impact of the rising interest rates designed to quell it, the Company continued to show solid revenue growth in its business. 2023 results showed revenue growth of $1,065,101 or 8.33% over the prior year, with a positive EBITDA of $1,067,247. The Company's cash position remained strong at $1,876,765, after cash dividend payouts of $351,679 to the common shareholders in June 2023.

    Ron Loucks, President and CEO, stated "With various investments that the Company made upfront to develop and maintain customer relationships, together with distribution of dividends, these results are a strong statement that reflects the Company's capability of generating free cash flow. 2023 marks the 20th anniversary of the incorporation of NexgenRx. This significant milestone is particularly gratifying to me as the Company continues to expand its reach in the marketplace with new and innovative product solutions. As always, I would like to acknowledge our loyal shareholders, Board of Directors for their dedication, advice and counsel; our hard-working staff and most importantly, the continuous support and trust of our customers, in their commitment to the NexgenRx Group of Companies."

    About NexgenRx
    NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software as a Service) Model.

    NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

    Caution Regarding Forward-Looking Statements
    Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The Company cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

    Seite 1 von 2



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continued revenue growth to $3,573,751 for the quarter …